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Abstract
Knowledge on mechanisms involved in early prediction of response to antidepressant medication
may help optimize clinical decisionmaking. Recent studies regarding response to pharmacotherapy
implicate resilience-like mechanisms and involvement of positive, rather than negative emotions.
The aim of the current study is to examine the contribution of early change in positive affect to the
prediction of response to pharmacotherapy. Positive and negative emotions were measured at
baseline and during the first week of pharmacotherapy, using experience sampling techniques. The
association between early change in positive and negative emotions and severity of depressive
symptoms at week six was examined in a sample of 49 depressed patients. The added benefits of
measuring early change in positive emotions compared to early Hamilton Depression Rating Scale
(HDRS) change alone were evaluated through model comparisons. Early improvement in positive
affect during the first week of treatment predicted the continuous HDRS score (β=−0.64, pb0.001),
response (50% reduction; OR=4.32, pb0.01), and remission (HDRS≤7;OR=9.29, pb0.001) at week
six with moderate to large effect sizes. Effects of early change in negative emotions were only half
as large and disappeared when evaluated simultaneously with early change in positive emotions.
When early change in positive emotions was added to themodels including early HDRS change only,
all threemodels improved significantly. In conclusion, early change in positive rather than negative
emotions best predicted response to treatment, supporting thenotion that antidepressants activate
resilience-like mechanisms. Moreover, monitoring of positive emotions in early stages of treatment
may improve clinical decision making.
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242 N. Geschwind et al.1. Introduction assessment technique in which participants are prompted toThe efficiency of depression treatment can be considerably
improved if current trial and error strategies are enriched
with accurate outcome predictors at an early stage of
treatment. In contrast to previous hypotheses on delayed
onset of treatment response (Quitkin et al., 1984), evidence
suggests that about 60% of the improvement occurring on
active antidepressant and placebo takes place during the
first two weeks of treatment (Posternak and Zimmerman,
2005). Several randomized or naturalistic studies as well as
meta-analyses have shown that early improvement after one
or two weeks of treatment strongly predicts later treatment
outcome (e.g., Henkel et al., 2009; Stassen et al., 2007;
Szegedi et al., 2009; Tadic et al., 2010). However, all these
studies on early improvement assessed symptom severity
with the Hamilton Depression Rating Scale (HDRS; Hamilton,
1960). The HDRS is a multidimensional instrument that
covers only a selected number of clinical symptoms and
neglects the assessment of positive emotions (Bagby et al.,
2004). Investigations that rely on the HDRS therefore provide
little information on the nature of emotional changes driving
long-term improvement in early responders. Better knowl-
edge on the emotional mechanisms involved in early
response may aid the development of better strategies for
assessing early response to treatment, thereby optimizing
clinical decision making and improving quality of life for
patients suffering from depression.
Although studies show that antidepressant use affects both
positive and negative emotion processing (e.g. Harmer et al.,
2010; Rawlings et al., 2010), recent studies suggest that
changes in positive rather than negative emotions may be
important in predicting recovery from depression. First,
recovery from depression was associated with increases in
the ability to experience reward in daily life, rather than
decreases in sensitivity to stress (Wichers et al., 2009).
Second, a high ability to experience positive emotions in
daily life was associated with both reduced risk of becoming
depressed in individuals with high genetic loading for
depression and increased resilience against the development
of affective symptoms (Geschwind et al., 2010;Wichers et al.,
2007, 2010). Third, Stassen et al. (2007) concluded that
antidepressants appear to trigger and maintain a common,
resilience-like mechanism that controls recovery from depres-
sion. Psychological resilience can be defined as the ability to
bounce back from negative emotional experiences (Block and
Kremen, 1996; Tugade and Fredrickson, 2004), and recent
studies show that positive, but not negative emotions, predict
psychological resilience (Cohn et al., 2009).
Based on the findings outlined above, we hypothesized that
early change in positive affect, rather than early change in
negative affect, would be an important predictor of response
to antidepressant treatment. Furthermore, we expected that
adding information on early change in positive affect to
information on early change in HRSD would significantly
improve early prediction models of recovery from depression.
We tested this hypothesis in a pre-existing longitudinal dataset
on depressed patients starting pharmacotherapy. Early change
in positive and negative emotions was measured using the
experience sampling method (ESM) at baseline and at the end
of the first week of pharmacotherapy. ESM is a momentaryreport on current emotions at random moments during the
day, and is ideally suited for investigating change in emotions
in daily life (Csikszentmihalyi and Larson, 1987).2. Experimental procedures
2.1. Sample
Eighty-three patients with a DSM-IV diagnosis of current major
depressive disorder (MDD) were recruited in eight primary care
practices in the Netherlands (for full details concerning diagnosis
and screening, see Barge-Schaapveld and Nicolson, 2002). Data were
collected in the period between 1995 and 1996. Inclusion criteria
were aged between 18 and 65 years and a score at study entry of≥18
on the 17-item Hamilton Depression Rating Scale (HDRS; Hamilton,
1960). Exclusion criteria included major medical disorders and
current use of psychotropic medications, except for the occasional
use of temazepam. All participants gave written informed consent.
The study was approved by the standing medical ethics committee.2.2. Study design
During an initial baselineweek, participants received no treatment in
any form and took part in the experience sampling procedure during
6 days. Those who had completed at least 30 valid experience
sampling assessments (for rationale see Experience sampling method
below) were randomly assigned to twice-daily, double-blind, six-
week treatment with either a tricyclic antidepressant or placebo
(imipramine: starting dose of 50 mg/day, increased to 200 mg/day
over the first week of treatment; placebo: starting with one capsule
per day, increased to 4 capsules over the first week of treatment). In
case of intolerance, the dose could be decreased to either 100 mg/day
of imipramine or 2 placebo capsules per day. Participants then took
part in a second period of experience sampling during the last three
days of the first week of treatment. In addition, patient's general
practitioners (GPs) administered the HDRS at screening, and at the end
of baseline, week 1, week 2, week 4 and week 6. The current report
used data from baseline, week 1 and week 6.2.3. Experience sampling method
The experience sampling method (ESM) is a momentary assessment
method to assess participants in their daily living environment,
providing repeated in-the-moment assessments of affect in a
prospective and ecologically valid manner (Csikszentmihalyi and
Larson, 1987). Participants received a digital wristwatch and a set of
ESM self-assessment forms collated in a booklet for each day. The
wristwatch was programmed to emit a signal (“beep”) at an
unpredictable moment in each of ten 90-minute time blocks between
7:30 and 22:30, on consecutive days, resulting in a maximum of 60
beeps per person for the baseline measurement and a maximum of 30
beeps for the last three days of the first week. After each beep,
participants were asked to fill out the ESM self-assessment, collecting
reports of current mood and context. All self-assessments were rated
on7-point Likert scales. Participantswere instructed to complete their
reports immediately after the beep, thus minimizing memory
distortion, and to record the time at which they completed the
form. Participants with less than one third of valid reports were
excluded from the analysis, and all reports not completed within
15 min after the actual beepwere considered invalid, as previous work
(Delespaul, 1995) has shown that reports completed after this interval
are less reliable and consequently less valid.
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2.4.1. Hamilton Depression Rating Scale (HDRS)
The 17-item HDRS (Hamilton, 1960) was administered by the
treating GP. All participating GPs had completed a standardized
training for the HDRS.
2.4.2. Positive affect (PA) and negative affect (NA)
At each beep, several ESMmood adjectives were assessed on 7-point
Likert scales ranging from 1 (not at all) to 7 (very), as described
previously (Barge-Schaapveld and Nicolson, 2002). The mood adjectives
‘cheerful’, ‘satisfied, ‘energetic’, ‘calm’, ‘enthusiastic’, ‘strong’ and
‘happy’ loaded on the PA factor (Cronbach's alpha=0.89), whereas
‘hostile’, ‘depressed’, ‘tense’, ‘insecure’, ‘lonely’, ‘anxious’, ‘guilty’,
‘harried’ and ‘irritable’ loaded on the NA factor (Cronbach's
alpha=0.85). Mean levels of PA and NA were computed for each
participant at each study period (baseline or end of week one)
separately.
2.5. Statistical analysis
2.5.1. Definitions of early change
Early changes in HDRS, NA and PAwere computed as the difference
between themeasure at baseline and at the endofweek one, such that
positive values reflect improvement (week one minus baseline for
HDRS and NA change, baseline minus week one for PA change).
2.5.2. Definitions of response and remission
In agreement with commonly used definitions (e.g., Ballesteros
et al., 2007; Henkel et al., 2009), response was defined as a reduction
of 50% ormore in HDRS score from baseline toweek 6, and remission as
a score of 7 or less on the HDRS at week 6.1
2.5.3. Statistical tests
Contributions of early change inPAandNA to improvement byweek
6 were examined separately, using three different definitions of
improvement: the continuous HDRS score at week 6, response, and
remission. Simple linear regressionwith covariateswas used to analyze
the relationship of early change in PA and NA, respectively, with the
continuous HDRS score at week 6, while correcting for baseline HDRS
score. Logistic regression was used for the dichotomous outcomes
response and remission. Because of our specific hypotheses on the
importance of PA, further analyses focussed on early change in PA.
Analyses explored to what extent early improvement in PA (compared
to early deterioration or no change in PA) predicted improvement at
week 6. Likelihood ratio tests were used to test whether early change
in PA provided additional information over and above early HDRS
change.
Imipramine and placebo groups were analyzed together, because
mechanisms and trajectories of recovery have been found to be similar
for antidepressant medication and placebo (Papakostas et al., 2006;
Posternak and Zimmerman, 2005; Stassen et al., 2007). Analyseswere,
however, corrected for group status (imipramine vs. placebo) and
repeated in each group separately to verify the assumption that early
change in PA predicted recovery from depression similarly in the
placebo and TCA group.
Because average levels of affect at baseline influence the extent of
possible change in PA or NA (i.e., ceiling or floor effects), all analyses
were corrected for participant's average PA or NA at baseline. All1 We chose to focus the analysis on outcome measures at week 6
because this is a clinically relevant time frame inwhich one can expect
major changes in depressive symptoms. However, all analyses yielded
similar results when repeated using definitions of stable response
(50% reduction at bothweek 4 andweek 6) and stable remission (≤7 at
week 4 andweek 6), orwhen a growthmodelwas used instead of linear
regression analyses.variables were standardized, except for the outcome variables
remission and response in the logistic regression. Standardized
regression coefficients β are reported for the linear regressions, and
Odd's Ratios (OR) for the logistic regressions. Analyses were performed
in Stata 11 (StataCorp, 2009).
3. Results
3.1. Participant characteristics
Of the 83 recruited patients, 9 were excluded on the basis of the
described inclusion and exclusion criteria. Additional 11 patients
completed fewer than 30 valid ESM reports at baseline, which was
the pre-set criterion for study continuation. Forty-nine of the
remaining 63 participants (78%) completed the first 6 weeks of
treatment. Seventeen of the 49 participants received imipramine,
and 22 placebo. Analyses were based solely on data of participants
who completed treatment. Dropouts showed a trend towards
higher PA at baseline, compared to completers (β=0.31, p=0.09).
There were no other significant baseline differences between
dropouts and completers, and dropout was not associated with
treatment group (imipramine vs. placebo).
Participants ranged in age from 25 to 59 years (mean=42.5,
SD=9.2). The majority were female (73%) and married (69%). Most
had regular jobs (47%) or were housewives (27%). Average HDRS
score ranged from 19 to 30 at baseline and from 0 to 24 at week 6.
Sixteen out of 49 participants were in remission in week 6, and 30
were classified as responders. Means and standard deviations of PA,
NA, and HDRS scores by study period are presented in Table 1. Only
10 out of 49 participants (5 in the imipramine group, and 5 in the
placebo group) experienced improvement of PA in the first week
(defined as PAweek 1NPA baseline), with no change orworsening in
the others. Participants with early improvement of PA did not differ
from the other participants in terms of socio-demographic
characteristics and severity of depression (all pN .20). Fig. 1 displays
average changes in PA, NA, and HDRS during the first week of
treatment, overall and stratified by response and remission status at
week 6.
3.2. Association of early change in PA and NA with
recovery from depression
Early change in PA during the first week of treatment significantly
predicted continuous HDRS scores as well as response and remission
at week six. As shown in Table 2, effect sizes of early change in PA
were moderate to large. Expressed in unstandardized values, an
increaseof onepoint (on the7-point Likert scale) inPA frombaseline
to week one corresponded to a 4-point decrease on the HDRS by
week six. Experiencing early improvement of PA, compared to no
change or early worsening of PA, was associated with a 9-point
decrease on the HDRS in week six (β=−0.54, pb0.001) and a 34
times higher probability of achieving remission (OR=33.90,
pb0.01). All 10 participants with early improvement of PA met
the response criterion at week six. Effect sizes of early change in PA
remained moderate to large when the analyses were repeated
separately for the placebo group (continuous: β=−0.54, pb0.01,
response: OR=3.89, pb0.05, remission: OR=6.52, pb0.05) and the
imipramine group (continuous: β=−0.63, pb0.01, response:
OR=5.38, p=0.07, remission: OR=20.41, pb0.05).
Although early change in NA also was a significant predictor
for the continuous HDRS sore and remission status (but not for
Table 1 Means and standard deviations (in brackets) of positive affect (PA), negative affect (NA) and Hamilton Depression Rating
Scale (HDRS) scores in the overall sample, and stratified by response and remission status.
Overall n=49 Response n=30 No response n=19 Remission n=16 No remission n=33
PA baseline 3.5 (1.4) 3.5 (1.6) 3.5 (1.2) 3.3 (1.6) 3.6 (1.4)
PA week 1 3.0 (1.4) 3.3 (1.5) 2.4 (1.0) 3.6 (1.4) 2.6 (1.2)
NA baseline 3.9 (1.3) 3.5 (1.3) 4.4 (0.9) 3.5 (1.4) 4.1 (1.1)
NA week 1 3.3 (1.5) 2.8 (1.3) 4.1 (1.4) 2.5 (1.0) 3.7 (1.5)
HDRS baseline 24.0 (3.2) 24.0 (3.6) 24.1 (3.1) 23.3 (3.8) 24.4 (2.9)
HDRS week 1 21.5 (4.7) 20.4 (5.1) 23.3 (3.5) 19 (5.3) 22.7 (3.9)
HDRS week 6 10.9 (6.5) 6.5 (3.4) 17.8 (3.5) 4.0 (2.5) 14.0 (5.0)
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of those for early change in PA (see Fig. 2). When early change
in PA and early change in NA were entered simultaneously to
check for the independence of their contributions, effect sizes
of early change in PA remained significant and similar in size
(continuous: β=−0.57, pb0.001, response: OR=4.00, pb0.05,
remission: OR=6.94, pb0.01), while the effects of early change
in NA decreased and were no longer statistically significant
(continuous: β=−0.12, pN .3, response: OR=1.32, pN .4, remis-
sion: OR=1.62, pN .4), indicating that the predictive value of NA
is reducible to that of PA.Figure 1 Average change in positive affect (PA), negative affect
(NA) and Hamilton Depression Rating Scale (HDRS) after one week
of treatment. The figure displays means (±SD) in the overall
sample as well as stratified by response (50% HDRS reduction) and
remission status (HDRS ≤7). Positive values reflect improvement,
while negative values reflect deterioration.3.3. Improvement of early predictionmodels through
addition of early change in PA
Early change in HDRS predicted significant improvement on all
three outcome measures (continuous: β=−0.48, pb0.001,
response:OR=4.08, pb0.05, remission:OR=2.36, pb0.05). When
early change in PA was added to the model including early change
in HDRS, all three models improved significantly (continuous: chi2
(2)=12.90, pb0.01; response: chi2(2)=6.24, pb0.05; remission
chi2(2)=14.72, pb0.001), with the proportion of explained
variance increasing from 30% to 44%, from 18% to 28%, and from
16% to 40%, respectively.
4. Discussion
Early change in positive affect (PA), compared to negative
affect (NA), best predicted response to treatment. Early
change in PA during the first week of treatment was associated
with improvement on the Hamilton Depression Rating Scale
(HDRS), response (50% symptom reduction), and remission
(HDRS ≤7) at week six. Effect sizes were moderate to large.
Early change in NA was not consistently associated with
response to treatment, and effect sizes were much smaller
than those of early change in PA. When both predictors were
entered into the regression model simultaneously, the effects
of NA change diminished even further, whereas effect sizes of
early change in PA remained similar. Compared tono change or
early worsening of PA, experiencing early improvement of PA
was associated with a 34 times higher chance of achieving
remission, and all 10 participants with early improvement of
PA achieved response at week six. Early PA improvement did
not depend on treatment group (imipramine or placebo).
Because participants with early improvement of PA did not
differ from the other participants in terms of socio-demo-
graphic characteristics and severity of depression, differences
in outcome can likely be attributed to changes in PA, rather
than to third variables associatedwith PA. Finally, adding early
change in positive emotions to standard early prediction
models significantly improved accuracy of prediction at week
six for all three outcome measures.
In order to speed up recovery from depression and provide
adequate treatment, it is useful to identify non-responders as
early and as accurately as possible. Early change in PA provided
vital information for prediction of response over and above
early HDRS change, which is still used as gold standard for the
assessment of depression, despite psychometrical and con-
ceptual flaws (Bagby et al., 2004). The HDRS unfortunately
Table 2 Standardized effect sizes and significance levels of early change in positive affect (PA) or negative affect (NA) on
Hamilton Depression Rating Scale (HDRS) score, response and remission at week 6 (first column).
Effect size Effect size Effect size Effect size
Early change PA Baseline PA Group Baseline HDRS
HDRS score (β) −0.64 ⁎⁎⁎ −0.34 ⁎ −0.35 ⁎⁎ 0.05
Response (OR) 4.32 ⁎⁎ 2.25 1.56 –
Remission (OR) 9.29 ⁎⁎⁎ 2.91 3.12 ⁎ –
Early change NA Baseline NA Group Baseline HDRS
HDRS score (β) −0.32 ⁎ 0.32 −0.24 0.07
Response (OR) 1.86 0.42 ⁎ 1.15 –
Remission (OR) 3.58 ⁎ 0.41 1.74 –
Analyses were corrected for baseline values of PA/NA and group status (TCA or placebo). The continuous HDRS analyses were additionally
corrected for baseline HDRS scores. For completeness, these effect sizes and p values are also displayed. Abbreviations: β = standardized
regression coefficient, OR = Odds Ratio.
⁎ pb0.05.
⁎⁎ pb0.01.
⁎⁎⁎ pb0.001.
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and Interest”, in which patients' capacity to work is assessed
simultaneously with their hospitalization status and levels of
interest in activities (Hamilton, 1960). We argue that
assessment of PAmay aid early identification of (non)response
and that assessment of PA should be includedwhenmonitoring
early treatment response. More research is needed before
determining clinically informative cut-off points which even-
tually could be used to aid clinical decision making involved in
the treatment of depression. Another unanswered question is
which time frame is best for assessing early changes in PA.
Early improvement in this study was very successful in
identifying responders to treatment (i.e., all early PA
improvers met the response criterion at week six). However,
the low rate of early PA improvement (compared to reported
rates of 65% of early HDRS improvement; Szegedi et al., 2009)
may mean that measuring PA change after two weeks could be
more successful in identifying non-response and need for
adjustment of treatment.
Because studies indicate that PA is associated with
resilience and well-being more strongly than NA (e.g., Cohn
et al., 2009; Fredrickson et al., 2003), our findings support
Stassen et al.'s (2007) claim that antidepressant treatment
may activate resilience-likemechanisms. Earlier studies found
that positive emotions were associated with attenuated
expression of genetic risk for depression and increased
resilience after adversity (Geschwind et al., 2010; Wichers
et al., 2008, 2007, 2010). Furthermore, in an experimental
setup, depressed participants differed from healthy controls
only regarding emotional response to anticipated reward but
not punishment (McFarland and Klein, 2009). The current
study adds to the accumulating evidence on the importance of
positive emotions in depression by showing that, after as early
as one week of treatment, the PA system reacts sensitively to
treatment and is closely linked to later response.Whether PA is
part of the resilience response or rather facilitates action of
other resilience-relatedmechanisms remains unclear and may
be investigated in future research.
Several large studies as well as meta-analyses demonstrate
that trajectories of recovery under active antidepressants —
once triggered — follow a pattern similar to that of placebo,despite marked pharmacologic differences of the triggers
(Posternak and Zimmerman, 2005; Stassen et al., 2007;
Szegedi et al., 2009; Tadic et al., 2010). Also in the current
study, early change in PA predicted response to treatment in
both the imipramine and the placebo group, implying over-
lapping mechanisms of recovery from depression in both
groups. As Stassen et al. (2007) argue, this may mean that
depressed patients have a biological resilience-like predispo-
sition that controls the time course of recovery and that can be
triggered, modified or suppressed. Our study suggests that
drugs — or psychotherapies — actively targeting the PA or
reward system may be particularly effective in activating
resilience mechanisms leading to recovery from depression.
Drugs that modulate catecholaminergic activity may increase
PA more than other types of drugs (Depue et al., 1994; Nutt
et al., 2007) because they tend to elevate dopamine activity in
the prefrontal cortex (Karson et al., 1983). Tugade and
Fredrickson (2004), for example, reported that the catechol-
aminergic action of bupropion SR produced more robust
effects on anhedonia than placebo (although see Dichter et
al., 2005). It is possible that drugs that facilitate early changes
in PA are more efficient in triggering recovery processes, even
though these differences in PA may disappear as time goes by
and patients recover from depression.
In conclusion, the involvement of positive emotions in early
response to antidepressant treatment supports the activation
of resilience-like mechanisms in recovery from depression.
Moreover, monitoring of positive emotions in early stages of
treatment may improve clinical decision making.
Limitations of the study include that evaluation of response
and remission took place in week 6. Our results need to be
replicated in studies with longer follow-up periods and larger
samples. Another limitation is that follow-upmeasurements of
dropouts were unavailable, possibly distorting the results.
However, analyses are likely to underestimate rather than
overestimate the effects of early PA improvement, given that
10 of 11 dropouts were participants with non-improvement of
PA. Finally, the relatively small sample size only allowed for
investigations of mechanisms of change common to placebo
and active antidepressant medication. However, several large
studies suggest that early improvementmechanisms appear to
Note: * p < 0.05  ** p < 0.01  *** p < 0.001 
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246 N. Geschwind et al.be similar in placebo and active drugs (e.g., Stassen et al.,
2007; Szegedi et al., 2009), and early change in positive affect
was an important predictor of improvement also when both
groups (placebo and imipramine) were examined separately.
Role of the funding source
This study was supported by a research grant from Solvay
Pharmaceuticals. Solvay Pharmaceuticals had no further role
in study design; in the collection, analysis and interpretation of
data; in the writing of the report; and in the decision to submit
the paper for publication.
Contributors
Authors Barge-Schaapveld and Nicolson designed the original study
and wrote the protocol. Wichers designed the analytical approach
for subsequent hypotheses, Geschwind and Wichers undertook the
statistical analysis, and Geschwind wrote the first draft of the
manuscript. All authors (Geschwind, Nicolson, Peeters, van Os,
Barge-Schaapveld, and Wichers) contributed to and have approved
the final manuscript.
Conflict of interest
Over the past three years, Jim van Os has been an independent
research grant holder or has received financial compensation as an
independent symposium speaker from Eli Lilly, BMS, Lundbeck,
Organon, Janssen-Cilag, GSK, Otsuka and AstraZeneca. Frenk Peeters
has received financial compensation as an independent speaker from
Wyeth, Glaxo-SmithKlineBeecham, Lundbeck and Astra Zeneca. All
other authors declare that they have no conflicts of interest.
Acknowledgements
We thank P. Verburg-Noteborn, C. van der Voort-Duindam, G.
Driesen and F. vanGoethemfor helpwith data collection andprocessing.
M. de Vries and P. Delespaul provided advice on various aspects of the
study. We are indebted to M. Bemelmans, R. Brouwers, G. Costongs, A.
Schlösser, J. Theunissen, P. van Aubel, D. van der Voort, and M. Weijtsfor subject recruitment and clinical assessments. The original study
was supported by an unrestricted research grant from Solvay Pharma-
ceuticals, Weesp, the Netherlands. M.C. Wichers was supported by the
Dutch Medical Council (VENI grant nr 916.76.147).
References
Bagby, R.M., Ryder, A.G., Schuller, D.R., Marshall, M.B., 2004. The
Hamilton Depression Rating Scale: has the gold standard become a
lead weight? Am. J. Psychiatry 161, 2163–2177.
Ballesteros, J., Bobes, J., Bulbena, A., Luque, A., Dal-Ré, R., Ibarra,
N., Güemes, I., 2007. Sensitivity to change, discriminative
performance, and cutoff criteria to define remission for embedded
short scales of the Hamilton Depression Rating Scale (HAMD).
J. Affect. Disord. 102, 93–99.
Barge-Schaapveld, D., Nicolson, N.A., 2002. Effects of antidepressant
treatment on the quality of daily life: an experience sampling
study. J. Clin. Psychiatry 63, 477–485.
Block, J., Kremen, A.M., 1996. IQ and ego-resiliency: Conceptual and
empirical connections and separateness. J Pers Soc Psychol 70,
349–361.
Cohn, M.A., Fredrickson, B.L., Brown, S.L., Mikels, J.A., Conway, A.
M., 2009. Happiness unpacked: positive emotions increase life
satisfaction by building resilience. Emotion 9, 361–368.
Csikszentmihalyi, M., Larson, R., 1987. Validity and reliability of the
experience sampling method. J. Nerv. Ment. Dis. 175, 526–536.
Delespaul, P.A.E.G., 1995. Assessing Schizophrenia in Daily Life. The
Experience Sampling Method. Maastricht University Press,
Maastricht.
Depue, R.A., Luciana, M., Arbisi, P., Collins, P., Leon, A., 1994.
Dopamine and the structure of personality: relation of agonist-
induced dopamine activity to positive emotionality. J. Pers. Soc.
Psychol. 67, 485–498.
Dichter, G.S., Tomarken, A.J., Freid, C.M., Addington, S., Shelton,
R.C., 2005. Do venlafaxine XR and paroxetine equally influence
negative and positive affect? J. Affect. Disord. 85, 333–339.
Fredrickson, B.L., Tugade, M.M., Waugh, C.E., Larkin, G.R., 2003.
What good are positive emotions in crises? A prospective study of
resilience and emotions following the terrorist attacks. J. Pers.
Soc. Psychol. 84, 365–376.
Geschwind,N., Peeters, F., Jacobs,N.,Delespaul, P.,Derom,C., Thiery,
E., van Os, J., Wichers, M., 2010. Meeting risk with resilience: high
daily life rewardexperiencepreservesmental health. Acta Psychiatr.
Scand. 122, 129–138.
Hamilton, M., 1960. A rating scale for depression. J. Neurol.
Neurosurg. Psychiatry 23, 56–62.
Harmer, C.J., de Bodinat, C., Dawson, G.R., Dourish, C.T.,
Waldenmaier, L., Adams, S., Cowen, P.J., Goodwin, G.M.,
2010. Agomelatine facilitates positive versus negative affective
processing in healthy volunteer models. J. Psychopharmacol.
doi:10.1177/0269881110376689.
Henkel, V., Seemuller, F.,Obermeier,M.,Adli,M., Bauer,M.,Mundt,C.,
Brieger, P., Laux, G., Bender, W., Heuser, I., Zeiler, J., Gaebel, W.,
Mayr, A., Moller, H.J., Riedel, M., 2009. Does early improvement
triggered by antidepressants predict response/remission? Analysis of
data from a naturalistic study on a large sample of inpatients with
major depression. J. Affect. Disord. 115, 439–449.
Karson, C., Kleinman, J., Berman, K., Phelps, B., Wise, C., DeLisi,
L., Jeste, D., 1983. An inverse correlation between spontaneous
eye-blink rate and platelet monoamine oxidase activity. Br. J.
Psychiatry 142, 43–46.
McFarland, B.R., Klein, D.N., 2009. Emotional reactivity in depression:
diminished responsiveness to anticipated reward but not to
anticipated punishment or to nonreward or avoidance. Depress.
Anxiety 26, 117–122.
Nutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin,M., Canonico,
P.L., Carrasco, J.L., Stahl, S., 2007. The other face of depression,
247Early improvement in positive emotion predicts remissionreduced positive affect: the role of catecholamines in causation
and cure. J. Psychopharmacol. 21, 461–471.
Papakostas, G.I., Perlis, R.H., Scalia, M.J., Petersen, T.J., Fava, M.,
2006. A meta-analysis of early sustained response rates between
antidepressants and placebo for the treatment of major
depressive disorder. J. Clin. Psychopharmacol. 26, 56–60.
Posternak, M.A., Zimmerman, M., 2005. Is there a delay in the
antidepressant effect? A meta-analysis. J. Clin. Psychiatry 148–158.
Quitkin, F.M., Rabkin, J.G., Ross, D., Stewart, J.W., 1984.
Identification of true drug response to antidepressants: use of
pattern analysis. Arch. Gen. Psychiatry 41, 782–786.
Stassen, H.H., Angst, J., Hell, D., Schayfetter, C., Szegedi, A., 2007. Is
there a common resilience mechanism underlying antidepressant
drug response? Evidence from 2848 patients. J. Clin. Psychiatry 68,
1195–1205.
StataCorp, 2009. Stata statistical software: Release 11. StataCorp LP,
College Station, TX.
Szegedi, A., Jansen, W.T., van Willigenburg, A.P.P., van der Meulen,
E., Stassen, H.H., Thase,M.E., 2009. Early improvement in the first
2 weeks as a predictor of treatment outcome inpatientswithmajor
depressive disorder: a meta-analysis including 6562 patients.
J. Clin. Psychiatry 70, 344–353.
Rawlings, N., Norbury, R., Cowen, P., Harmer, C., 2010. A single dose
of mirtazapine modulates neural responses to emotional faces in
healthy people. Psychopharmacology 1–10.
Tadic, A., Helmreich, I., Mergl, R., Hautzinger, M., Kohnen, R.,
Henkel, V., Hegerl, U., 2010. Early improvement is a predictor oftreatment outcome in patients with mild major, minor or
subsyndromal depression. J. Affect. Disord. 120, 86–93.
Tugade, M.M., Fredrickson, B.L., 2004. Resilient individuals use positive
emotions to bounce back from negative emotional experiences.
J Pers Soc Psychol 86, 320–333.
Wichers, M.C., Barge-Schaapveld, D.Q.C.M., Nicolson, N.A., Peeters, F.,
de Vries, M., Mengelers, R., van Os, J., 2009. Reduced stress-
sensitivity or increased reward experience: the psychological
mechanism of response to antidepressant medication. Neuropsycho-
pharmacology 34, 923–931.
Wichers, M.C., Kenis, G., Jacobs, N., Myin-Germeys, I., Schruers, K.,
Mengelers, R., Delespaul, P., Derom, C., Vlietinck, R., van Os, J.,
2008. The psychology of psychiatric genetics: evidence that
positive emotions in females moderate genetic sensitivity to social
stress associated with the BDNF val(66)met polymorphism.
J. Abnorm. Psychol. 117, 699–704.
Wichers, M.C., Myin-Germeys, I., Jacobs, N., Peeters, F., Kenis, G.,
Derom, C., Vlietinck, R., Delespaul, P., Van Os, J., 2007. Genetic
risk of depression and stress-induced negative affect in daily life.
Br. J. Psychiatry 191, 218–223.
Wichers, M.C., Peeters, F., Geschwind, N., Jacobs, N., Simons, C.J.P.,
Derom, C., Thiery, E., Delespaul, P.H., Os, J.v., 2010. Unveiling
patterns of affective responses in daily life may improve outcome
prediction in depression: amomentary assessment study. J. Affect.
Disord. 124, 191–195.
